In contrast, a third group of patients, those with FLT3-ITD positive AML and co-occurring high-risk genetic changes (trisomy 8, TET2 and/or DNMT3A) had an OS curve that was significantly different from that of the intermediate IGP risk group and similar to that of patients with unfavorable cytogenetics. The gene discussed is TET2; the disease is acute myeloid leukemia.